Jointly provided by Medical Education Resources and Impact Education, LLC.
Dinner and drinks provided by Impact Education, LLC.
|
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
|
Wednesday, April 3, 2024
6:00 PM - 6:30 PM - Registration and Reception
6:30 PM - 9:00 PM - Dinner and Presentation
Maggiano's Little Italy
16405 N Scottsdale Rd
Scottsdale, AZ 85254
|
This CE program is intended for managed care and payer professionals from health plans, PBMs, integrated health systems, and other payer organizations. Others who wish to register may be added to a wait list based on venue capacity.
|
|
Expert Faculty
|
|
Who Should Attend?
|
This activity is designed to meet the educational needs of Southwest AMCP affiliate members in the roles of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
Participate in the pre-program survey: Click Here
|
|
Statement of Need/Program Overview
|
Within the space of just a few years, several new retinal treatments have been approved for age-related macular degeneration (AMD) and diabetic retinopathy/diabetic macular edema (DR/DME), promising increased durability and better patient outcomes. These conditions can significantly impact vision and quality of life for patients. Retinal specialists are using a combination of traditional therapies, such as anti-vascular endothelial growth factor (anti-VEGF) injections, as well as emerging therapies, like sustained-release drug delivery systems, and other innovative approaches. The involvement of payers in the management of retinal diseases is essential to ensure that treatments are accessible to patients who need them. It is an exciting time in the field of retinal medicine, with advancements in treatment options and the opportunity for collaboration between retinal specialists and payers to improve the quality of patient care while also managing costs.
|
|
Educational Objectives
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Assess evidence-based treatment strategies and resources for optimal patient outcomes in diabetic retinopathy/diabetic macular edema (DR/DME) and age-related macular degeneration (AMD)
- Characterize pharmacologic treatment options for DR/DME and AMD in terms of efficacy, safety, and dosing intervals
- Employ regional benefit design strategies that facilitate appropriate patient access to evidence-based treatment options for DR/DME and AMD
- Implement collaborative regional payer/provider initiatives to improve the treatment of DR/DME and AMD
|
|
Agenda
|
Date and Time
Wednesday, April 3, 2024
6:00 PM - 6:30 PM - Registration and Reception
6:30 PM - 9:00 PM - Dinner and Presentation
Maggiano's Little Italy
16405 N Scottsdale Rd
Scottsdale, AZ 85254
|
Evidence-Based Treatment of AMD and DR/DME
- Disease overviews
- Treatment goals and key considerations
- Guidelines and treatment recommendations
|
Improving Care with Treatment Innovation and Patient Engagement
- Innovative and emerging treatment options
- Patient case presentation
|
Moderated Region Panel Discussion
- Understanding regional perspectives on retinal diseases
- Regional opportunities to improve the quality of care
- Collaborative opportunities and health plan best practices
|
|
Accreditation Information
|
|
Joint Accreditation Statement |
 |
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0003680-9999-23-162-L01-P
Type of Activity: Knowledge
Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
|
Continuing Nursing Education
Medical Education Resources designates this live activity for a maximum of 1.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
|
Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
| Name of Faculty/Planners |
Reported Financial Relationship |
| Mark R. Barakat, MD |
Grants/Research Support: Adverum Biotech, Annexon Biosciences, CalciMedica, Clearside Biomedical, EyeBio, EyePoint Pharma, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Kanghong/Vanotech, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Perfuse, RegenxBio, ReNeuron, Ribomic, Roche, Stealth Biotherapeutics, Unity Biotechnology
Consulting Fees: AbbVie Inc, Adverum Biotech, Alcon, Alimera, Allegro, Allergan, AmerisourceBergen, Annexon, Apellis, Arctic Vision, Bausch and Lomb, Biogen, CalciMedica, Clearside Biomedical, Coherus Biosciences, EyePoint Pharma, Genentech, Kodiak Sciences, lveric Bio, Janssen, Neurotech, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, RegenxBio, RevOpsis Therapeutics, Roche, Stealth Biotherapeutics
Speakers' Bureau: Apellis, Bausch and Lomb, Genentech, lveric Bio, Novartis, Regeneron
Ownership Interest/Shareholder: NeuBase, Oxurion, RevOpsis Therapeutics |
|
|
|
|
The MER planners and managers have nothing to disclose.
The Impact Education, LLC planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information
There is no fee for this educational activity.
|
| | |
